A multicentre prospective cohort study assessing the effectiveness of budesonide MMX(R) (Cortiment(R)(MMX(R))) for active, mild-to-moderate ulcerative colitis.
Danese, Silvio; Hart, Ailsa; Dignass, Axelet al.
2019 • In United European Gastroenterology Journal, 7 (9), p. 1171-1182
[en] Background: Cortiment(R)(MMX(R)) (budesonide MMX(R)) is currently approved for the induction of remission in mild-to-moderate ulcerative colitis (UC) patients when 5-ASA treatment is not sufficient. Data in real-life settings are lacking. Methods: This was a multicentre observational prospective cohort study conducted in Europe and Canada. Effectiveness, safety, and tolerability of Cortiment(R)(MMX(R)) in a real-life setting of patients treated for mild-to-moderate UC was investigated. Patients were prescribed Cortiment(R)(MMX(R)) in accordance with the Summary of the Product Characteristics (SmPC).The primary endpoint was the clinical benefit of Cortiment(R) MMX(R) in routine practice (improvement >/= 3 points in the clinical sub-scores of the Ulcerative Colitis Disease Activity Index, UCDAI). Results: Data from 326 patients with mild-to-moderate UC were analysed for the primary endpoint. Clinical benefit was achieved in 60.1% (196/326) of patients at the end of Cortiment(R)(MMX(R)) treatment. Clinical remission (UCDAI clinical sub-score </= 1), full symptoms resolution (rectal bleeding (RB) = 0 and stool frequency (SF) = 0) and symptoms resolution (RB = 0 + SF </= 1) at the end of the Cortiment(R)(MMX(R)) treatment were achieved in 51.8%, 45.1% and 63.2% of patients, respectively. The median time to symptoms resolution was 30 days (range 29.0-36.0 days). Fifty patients (14.3%) had to discontinue Cortiment(R)(MMX(R)) due to adverse events; 17.5% of patients (n = 61) reported at least one adverse event related to the study drug. Conclusions: This was the first time that a large cohort study was conducted with Cortiment(R)(MMX(R)) in a real-life setting. It demonstrated that Cortiment(R)(MMX(R)) is effective, safe and well tolerated in about 60% of UC patients.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Danese, Silvio
Hart, Ailsa
Dignass, Axel
Fiorino, Gionata
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Bonovas, Stefanos
D'Haens, Geert
Dotan, Iris
Rogler, Gerhard
Paridaens, Kristine
Peyrin-Biroulet, Laurent
Language :
English
Title :
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX(R) (Cortiment(R)(MMX(R))) for active, mild-to-moderate ulcerative colitis.
Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011; 365: 1713–1725.
Solberg IC, Lygren I, Jahnsen J, Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009; 44: 431–440.
Peyrin-Biroulet L, Sandborn W, Sands BE, Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015; 110: 1324–1338.
Magro F, Gionchetti P, Eliakim R, Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 2017; 11: 649–670.
Harbord M, Eliakim R, Bettenworth D, Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis 2017; 11: 769–784.
Bonovas S, Nikolopoulos GK, Lytras T, Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: systematic review and network meta-analysis. Br J Clin Pharmacol 2018; 84: 239–251.
Gomollón F, Dignass A, Annese V, 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016. Part 1: diagnosis and medical management. J Crohns Colitis 2017; 11: 3–25.
Travis SPL, Danese S, Kupcinskas L, Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014; 63(3): 433–441.
Brunner M, Ziegler S, Di Stefano AF, Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br J Clin Pharmacol 2006; 61: 31–38.
McCormack PL, Robinson DM, Perry CM. Delayed-release Multi Matrix System (MMX) mesalazine: in ulcerative colitis. Drugs 2007; 67: 2635–2642.
Nicholls A, Harris-Collazo R, Huang M, Bioavailability profile of Uceris MMX extended-release tablets compared with Entocort EC capsules in healthy volunteers. Journal Int Med Res 2013; 41: 386–394.
Prantera C, Viscido A, Biancone L, A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005; 11: 421–427.
Tenjarla S, Romasanta V, Zeijdner E, Release of 5-aminosalicylate from an MMX mesalamine tablet during transit through a simulated gastrointestinal tract system. Adv Ther 2007; 24: 826–840.
D'Haens GR, Kovacs A, Vergauwe P, Clinical trial: preliminary efficacy and safety study of a new Budesonide-MMX(R) 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. J Crohns Colitis 2010; 4: 153–160.
Sandborn WJ, Travis S, Moro L, Once-daily budesonide MMX(R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012; 143: 1218–1226.
Lichtenstein GR, Travis S, Danese S, Budesonide MMX for the induction of remission of mild to moderate ulcerative colitis: a pooled safety analysis. J Crohns Colitis 2015; 9: 738–746.
Ma C, Panaccione R, Fedorak RN, Heterogeneity in definitions of endpoints for clinical trials of ulcerative colitis: a systematic review for development of a core outcome set. Clin Gastroenterol Hepatol 2018; 16: 637–647.
Irvine EJ, Zhou Q, Thompson AK The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn s Relapse Prevention Trial. Am J Gastroenterol 1996; 91(8): 1571–1578.
Han SW, Gregory W, Nylander D, et al. The SIBDQ: Further validation in ulcerative colitis patients. The American Journal of Gastroenterology 2000; 95(1): 145–151.
Jowett SL, Seal CJ, Barton JR, et al. The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis. The American Journal of Gastroenterology 2001; 96(10): 2921–2928.
Reilly MC, Zbrozek AS, & Dukes E. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmaco Economics 1993; 4(5): 353–365.
de Boer AG, van Lanschot JJ, Stalmeier PF, et al. Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life? Quality of Life Research 2004; 13(2): 311–320
Brokelman RBG, Haverkamp D, et al. The validation of the visual analogue scale for patient satisfaction after total hip arthroplasty. Eur Orthop Traumatol 2012; 3: 101–105.
